Annovis Bio Inc. (NYSE: ANVS) reported first-quarter 2026 business and financial results, highlighting continued advancement of its clinical-stage neurodegenerative disease programs. The company announced that its pivotal Phase 3 Alzheimer’s disease trial has reached 85% enrollment and that enrollment has been closed to new participants after achieving sufficient screening levels to meet enrollment goals.
In addition to the Alzheimer’s trial progress, Annovis reported that its Parkinson’s disease open-label extension study has reached 40% enrollment. The company is also pursuing new biomarker initiatives and AI-powered digital monitoring as it continues advancing buntanetap toward potential regulatory submission.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The progress in both Alzheimer’s and Parkinson’s programs marks an important step for the company as it advances late-stage clinical trials for conditions that affect millions worldwide. Alzheimer’s disease is the most common form of dementia, affecting an estimated 6.7 million Americans, while Parkinson’s disease impacts approximately 1 million people in the U.S. Successful development of buntanetap could provide a new treatment option for patients with these debilitating neurodegenerative diseases.
“The closure of enrollment in our Phase 3 Alzheimer’s trial after reaching 85% enrollment is a significant milestone,” said a company representative in the press release. “We are encouraged by the progress across both our Alzheimer’s and Parkinson’s programs and remain focused on advancing buntanetap toward potential regulatory submission.”
Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania. The company develops treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).
For more information on the full press release, visit https://ibn.fm/M77X4. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
